About this trial
Previous data from our group showed reduced BMPR2 isoform A in pulmonary hypertension associated with left heart disease (PH-LHD) of valvular origin.
Focusing on dysregulation of the BMPR2-activin pathway, a key regulator of vascular homeostasis, this project uses a multimodal approach combining molecular biology, advanced cardiac imaging, and histology.
Its aim is to determine the role of the BMPR2-activin pathway in the development and regression of PH-LHD.
We will conduct a prospective observational study with 1-year follow-up in 150 heart failure patients of different etiologies undergoing hemodynamic assessment.
Clinical parameters, biomarkers, molecular profiles, and hemodynamic/echocardiographic variables will be analyzed.
A nested substudy in 40 heart transplant candidates will include thoracic CT for vascular morphometric analysis and histological correlation in explanted hearts versus healthy controls.
We will also assess reversibility of vascular remodeling one year after transplantation.
Results may redefine PH-LHD classification, enable phenotypic precision-medicine models, guide targeted therapies such as activin inhibitors, and refine transplant criteria in combined pulmonary hypertension.
Eligibility criteria
Qualifiers
Older that 18 years
Heart failled patients with clinical indication for invasive hemodynamic assessment
Written consent
Disqualifiers
Refulsl to sign the infomred consent
Presence of iodinated contrast allergy
Ineligibility for HT (for BREATHE-CT substudy)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Hospital General Universitario Gregorio Marañon
Lead sponsor
Fundacion para la Innovacion en Biomedicina (FIBMED)
Collaborator
Instituto de Investigación Sanitaria Gregorio Marañón
Collaborator